Cognitive Neurophysiology Laboratory, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York
Departments of Biostatistics and Epidemiology, New York State Psychiatric Institute, New York
Division of Child Behavioral Health, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
Department of Psychiatry, New York University School of Medicine, New York
Joseph Mailman School of Public Health, Columbia University, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, USA
Correspondence: Megan A. Perrin, The Cognitive Neurophysiology Laboratory, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, New York 10962, USA. Tel: +1 845 398 6547; fax: +1 845 398 6545; email: mperrin{at}nki.rfmh.org
Funding detailed in Acknowledgements.
|
|
|---|
Aims To assess the association between early life/later childhood growth patterns and risk of schizophrenia.
Methods Using prospectively collected data from a birth cohort (born 1959–1967), measurements of height, weight and body mass index (BMI) were analysed to compare growth patterns during early life and later childhood between 70 individuals with schizophrenia-spectrum disorder (SSD) and 7710 without.
Results For women, growth in the SSD group was approximately 1 cm/year slower during early life (P < 0.01); no association was observed for men. Later childhood growth was not associated with SSD. Weight patterns were not associated with SSD, whereas slower change in BMI was observed among the SSD group during later childhood.
Conclusions The association between slower growth in early life and schizophrenia in women suggests that factors responsible for regulating growth might be important in the pathogenesis of the disorder.
|
|
|---|
|
|
|---|
The study reported here is restricted to a cohort referred to as the Prenatal Determinants of Schizophrenia (PDS) study cohort, which is a subsample of the offspring of those participating in the CHDS. The design for the PDS study cohort has been previously described in full (Susser et al, 2000); thus, only a summary is provided here. The PDS study cohort was designed to follow up and assess participants for the presence of schizophrenia-spectrum disorders in order to evaluate developmental determinants of schizophrenia. It included offspring of mothers from the CHDS cohort who were members of KFHP from 1 January 1981 to 31 December 1997 (n=12 094). These dates correspond to the period of case ascertainment, which commenced when KFHP began using computerised records, making it feasible to identify all members who had accessed mental health services. Participants in the PDS cohort are comparable with the CHDS sample, with two exceptions: mothers of African American ethnicity were more likely to be included in the PDS cohort (CHDS 16%, PDS 28%) and offspring of low-income unmarried mothers were somewhat less likely to be included (CHDS 26, PDS 20%).
Height measurements
Height in inches to the nearest sixteenth of an inch (1.6 mm) was measured
and recorded during regular paediatric visits from birth to age 13 years.
These measurements were systematically abstracted from medical records by
trained CHDS abstractors. The present analyses were restricted to data from
birth to age 9 years, since reliable data on the pubertal stage of development
were not available. The average number of height measurements between birth
and age 2
years was 9 for both the schizophrenia-spectrum disorder
(SSD) group and the non-SSD group ranging from 3 to 15 measurements for the
former and 1 to 31 for the latter. Between ages 2
years and 9 years
the average number of height measurements was 6 for both groups, ranging from
1 to 19 measurements for the SSD group and 1 to 41 for the non-SSD group. To
identify outliers, height was standardised by computing gender- and
age-adjusted means using the least mean squares (LMS) method
(Cole, 1990). This method is
advantageous for standardising height because it uses a series of calculations
to reduce asymmetry in skewed data. Height measurements that were greater than
4 standard deviations above or below the mean were considered to be outliers
and were excluded from the analyses; 1.0% of all measurements were
excluded.
Assessment of potential confounders
Potential confounding factors were determined a priori based on
characteristics that have been shown to be associated with both height and
schizophrenia. These included gender, maternal race and education,
standardised maternal height, pre-pregnancy body mass index (BMI), gestational
age at birth and birth weight. (It is unnecessary to control for birth length
in the adjusted analysis because it is used to estimate growth patterns.)
Demographic measures were assessed through maternal interview, which was
completed during the first prenatal visit.
Maternal race was categorised as White, Black or other. Maternal education was rated on a seven-point scale reflecting the highest level of education achieved. Because not all levels of education were represented among the SSD sample, the categories were collapsed as follows: less than high-school diploma, high-school graduate with or without trade school, high-school graduate plus 1–3 years of college, and college graduate.
Maternal height was measured during the maternal interview. Because
paternal height was based on maternal report and we had insufficient data on
paternal height, standardised maternal height was used as a proxy for the
child's genetic growth potential. Standardisation of maternal height was
accomplished using the LMS method. Because adult height is not typically
achieved until 20 years of age, z-score transformations of height for
mothers aged 15–19 years were calculated separately at 1-year intervals.
Mothers aged 20 years or over were assumed to have attained their adult height
and were standardised as one group irrespective of age. Maternal pre-pregnancy
BMI was calculated using self-reported weight prior to pregnancy and was
classified based on categories used in a previous study assessing the
association between maternal BMI and schizophrenia-spectrum disorders in this
cohort: low,
19.9 kg/m2; average, 20.0–26.9
kg/m2; greater than average, 27.0–29.9 kg/m2;
high,
30.0 kg/m2)
(Schaefer et al,
2000). Maternal pre-pregnancy BMI data were missing in a
proportion of the sample (8 SSD and 1166 non-SSD). To preserve sample size,
the average maternal BMI value was substituted for missing data in the
adjusted analyses. Gestational age at birth was calculated as the number of
days between the last reported menstrual period and birth.
Ascertainment and diagnosis
We identified potential cases of schizophrenia-spectrum disorder through
the KFHP computerised records of in-patient, out-patient and pharmacy
registries. With regard to the hospitalisation registry, potential cases were
first identified if the individual had received ICD–9 diagnosis codes of
295, 296, 297, 298 or 299 (World Health
Organization, 1978) or were not given a specific diagnosis. A
review of psychiatric and medical records by a psychiatrist was conducted to
determine whether individuals screened positive for evidence of a psychotic
disorder. Individuals from the out-patient registry were considered to be
screen-positive for SSD if they had diagnosis codes of 295, 297, 298 or 299.
For the pharmacy registry, cases screened positive if the individual had
received treatment with antipsychotic medication.
We identified 183 participants for further diagnostic assessment. Of those identified, 13 had died. Of the 170 remaining, 146 (86%) were successfully contacted and 107 (58% of those originally identified) completed the Diagnostic Interview for Genetic Studies (DIGS; Nurnberger et al, 1994) administered by a trained research clinician. For the remaining 76 (42%) individuals who were not interviewed, a diagnosis was made based on review of the medical records by trained clinicians. All individuals provided written informed consent for participation prior to the diagnostic interview. Informed consent was approved by the institutional review boards of the New York State Psychiatric Institute and the Kaiser Permanente Division of Research. Diagnoses were made by consensus of three diagnosticians who independently reviewed all relevant material for each case. In total, 71 cases were identified (43 schizophrenia, 17 schizoaffective disorder, 5 schizotypal disorder, 1 delusional disorder and 5 other schizophrenia-spectrum psychosis). Forty-four individuals completed the DIGS and 27 were diagnosed by chart review.
Analytical data-set
The PDS cohort comprised 12 094 individuals –71 SSD and 12 023
non-SSD. Because our analysis required information obtained through maternal
interview during enrolment, people who had not completed the interview were
excluded (n= 2412), reducing the sample size to 9682. Since siblings
represent non-independent observations, only one sibling per family was
included in the analysis and siblings of offspring with schizophrenia-spectrum
disorder were excluded (n=1886). Two people in the SSD group were
siblings, so one of them was randomly selected and the data excluded from the
analysis. The final cohort consisted of 7795 persons. Please see Susser et
al (2000) for a further
description of the method for deriving the analytic sample. From this cohort
only 15 individuals (all from the non-SSD group) were excluded because they
did not have at least one valid height measurement; thus, the analytic sample
comprised 7780 persons (SSD n=70; non-SSD n=7710). A summary
of the exclusion criteria for the analytical data-set is provided in
Fig. 1.
![]() View larger version (18K): [in a new window] [as a PowerPoint slide] |
Fig. 1 Study profile (PDS, Prenatal Determinants of Schizophrenia).
|
The first step in the analyses was to determine the best model fit for the
relationship between growth and age from birth to 2
years, which is
referred to as the basic growth model. We first examined the mean level model,
which is the between-participant differences in mean level of height (i.e.
height=β0+error). The results suggested that between
participants differences were found for height; the estimated variance of the
mean height was 2.06 (s.e.=0.28, P < 0.001). To determine the best
model for predicting growth, we compared three additional models: linear
change in height (height=β1+age+error), quadratic change in
height (height=β2+ age+age2+error) and cubic change
in height
(height=β3+age+age2+age3+error), where
random variation was permitted for each age term. To estimate model fit, we
calculated the chi-squared value by subtracting the –2 log likelihood
estimates from the subsequent models (i.e. mean level v. linear,
linear v. quadratic, and quadratic v. cubic). Compared with
the mean level model, the addition of the linear term significantly improved
model fit (P < 0.001). The addition of the quadratic term also
significantly improved model fit compared with the linear model (P
< 0.001). Also, the cubic model appeared to significantly improve model fit
compared with the quadratic model (P < 0.001). However, the fixed
effect of the cubic term was small and the significant improvement mostly due
to the random effects. Also, the addition of the cubic term reduced the
variance associated with the linear term to zero. Therefore, to facilitate
interpretation, and in the interest of comparability and parsimony, we chose
to use the quadratic model. Although fractional polynomial models are
sometimes used in this type of analysis, a quadratic equation appears to be an
accurate estimate of growth and is easier to interpret. In summary, the model
comparisons suggested that the quadratic model provided the best model fit for
estimating patterns of growth.
Once the basic model for growth was established, we fitted a conditional
model to examine the effect of schizophrenia-spectrum disorders on growth. We
added SSD (1, case, 0, non-case) as a covariate to examine mean level
differences in height. To assess growth differences between the SSD and
non-SSD groups, we included an interaction term for age and SSD and an
interaction term for (age)2 and SSD in the quadratic model. All
adjusted analyses controlled confounding effects of gender, maternal
education, race, BMI and height, gestational age at birth and birth weight.
Each model included a
2-test of improvement of fit to the
data.
Using the methods described above we also estimated the basic model for
growth from age 2
to 9 years. Separate analyses were performed for
early life (birth to age 2
years) and later childhood (2
to 9
years) because growth during these periods is regulated by different
mechanisms (Karlberg, 1987;
Reiter & Rosenfeld, 2003).
Additionally, previous research suggests that growth during the first 2 years
of life is more variable than growth in later childhood and abnormal growth
patterns may be indicative of problems during prenatal development
(Tanner, 1994;
Reiter & Rosenfeld, 2003).
Hence, we predicted that early life (birth to 2
years) would be
associated with the most pronounced growth deficit in individuals who later
developed schizophrenia. Previous studies also demonstrated gender differences
in growth patterns in healthy samples
(Karlberg, 1987) and in the
risk and correlates of schizophrenia
(Goldstein et al,
2002; Aleman et al,
2003). Thus, all analyses were performed on the entire cohort as
well as being further stratified by gender in order to determine whether
differences in growth patterns between individuals in the SSD and non-SSD
groups varied by gender.
In addition to assessments using the multilevel growth model, we calculated
the linear slope (linear change in height by age) for each participant by
using maximum likelihood estimates from the basic growth models for both early
life (birth to age 2
years) and later childhood (2
to 9
years). A feature of this program is the ability to output the empirical
Bayesian estimates of the linear slope of height for each participant over the
defined periods (McArdle et al,
2005). The linear slopes provide additional information about
differences between the SSD and non-SSD groups observed from the multilevel
models.
|
|
|---|
|
View this table: [in a new window] |
Table 1 Sample characteristics (n=7780)
|
Change in height
The first step in the analyses was to determine the best model fit for
estimating growth in our cohort, which is referred to as the basic model. As
noted in the statistical analysis section, we determined that the quadratic
model, allowing between-participant variance, provided the best model fit for
estimating growth (i.e. height=β0+age+age2+error).
With respect to the early-life model, the average height at birth for the
entire sample was 52.06 cm (Table
2). On average, female babies were 0.82 cm shorter at birth than
the males (51.64 cm and 52.46 cm respectively). For the entire sample there
was a linear increase with age of 30.27 cm per year
(Table 2). Rates of growth
declined with age and were best described by a model with a linear and
quadratic term. In accordance with normal growth patterns
(Karlberg, 1987), growth
during childhood was slower than during early life and the girls remained
shorter than the boys (Table
2).
|
View this table: [in a new window] |
Table 2 Estimated fixed effects assessing the basic growth model
|
Association between potential confounders and height
We found the expected relationships between the confounders and variability
in height at birth and age 2
years. Compared with the White
participants, Black participants were significantly shorter at birth but
taller at age 2
years. Mothers with a higher level of educational
attainment tended to have offspring who were taller at birth and at age
2
years. Pre-pregnancy maternal BMI was positively correlated with
birth length, and greater gestational age at birth was associated with
increased birth length and height at age 2
years.
Association between growth velocity and SSD
The results from the final models assessing the relationship between change
in height and schizophrenia-spectrum disorders are presented in
Table 3. Each model controlled
for all main effects; however, only relevant estimates are presented; the
results for all interaction terms are presented in the online data supplement
to this paper. In Table 3, the
term representing the final estimate for the relationship between growth and
schizophrenia spectrum disorders is labelled the `Effect of gender and SSD on
growth, cm/year)'. Gender was included in the final estimate because patterns
of growth differ between males and females
(Karlberg, 1987). Furthermore,
one of the goals of the analyses was to explore gender differences in the
relationship between growth and schizophrenia. This estimate indicated that in
SSD group growth was approximately 1 cm per year slower during early life than
in the non-SSD group (B=–1.12, 95% CI –2.04 to –0.20,
P=0.017), and the difference was significantly modified by gender.
The difference was greater after controlling for potential confounders
(B=–1.55, 95% CI –2.52 to –0.57, P=0.002). In
analyses stratified by gender, in females in the SSD group growth was
approximately 1 cm per year slower than in the non-SSD group (females only
model; unadjusted, B=–1.03, 95% CI –1.73 to –0.33,
P=0.004; adjusted, B=–1.26, 95% CI –2.00 to –0.53,
P=0.001). No significant difference in growth velocity between males
in the SSD and non-SSD group was observed. There was no overall or
gender-specific difference in birth length between the groups or in isolated
measures of height (Table
3).
|
View this table: [in a new window] |
Table 3 Estimated fixed effects assessing growth patterns and adult
schizophrenia
|
Table 4 provides the average linear slope stratified by gender and SSD status. Dunnett's two-sided t-tests were used to compare the linear change in growth between groups stratified by gender. `Male non-SSD' was used as the reference category. The results suggest that females with SSD, on average, grew 0.84 cm per year slower than males without SSD (P < 0.001); and females without SSD grew 0.23 cm per year slower than males without (P < 0.001). There was no sigificant difference in growth between males with and without SSD (Fig. 2).
|
View this table: [in a new window] |
Table 4 Differences in linear growth stratified by gender for participants with and
without schizophrenia-spectrum disorders (SSD)
|
![]() View larger version (15K): [in a new window] [as a PowerPoint slide] |
Fig. 2 Early-life growth trajectory and schizophrenia-spectrum disorders
(SSD).
|
In contrast to early life, patterns of growth during later childhood were not significantly different between the SSD and non-SSD groups (B=–0.16, 95% CI –0.61 to 0.29, P=0.478), even after controlling for potential confounders (B=–0.21, 95% CI –0.70 to 0.28, P=0.389) (Table 3). Although we did not include the linear growth models stratified by gender for later childhood, the average linear growth estimates (Table 4) showed that girls in the SSD group continued to grow slightly more slowly, but the difference was no longer statistically significant.
In addition to assessing patterns of growth using measures of height, we also examined changes in weight and BMI. Birth weight did not differ between the SSD and non-SSD groups even after stratifying by gender. Weight gain was slightly slower in the SSD group during early life (adjusted models, B=–0.21; 95% CI=–0.64 to 0.22, P=0.342) and later childhood (B=–0.28; 95% CI–0.66 to 0.11, P=0.160), but the effect was not statistically significant. Change in BMI during infancy was comparable between the SSD and non-SSD (adjusted models, B=0.07, 95% CI –0.49 to 0.62, P=0.814). During later childhood there was a trend toward a slower change in BMI in the SSD group (adjusted models, B=–0.23, 95% CI –0.46 to 0.01, P=0.059).
|
|
|---|
Our results are consistent with conclusions drawn from a previous study suggesting that the presence of delayed physical growth during early life is associated with later schizophrenia (Fish, 1959). However, that study, unlike ours, looked at a small high-risk sample, which included offspring of mentally ill parents, and thus the conclusions may not be generalisable to other populations. We have extended these findings by demonstrating this effect in a population-based cohort.
Catch-up growth and schizophrenia
Catch-up growth occurs when a period of delayed growth is followed by
accelerated growth, beyond the normal rate for age
(Kay's & Hindmarsh, 2006).
Previous assessments of growth patterns in individuals with psychosis suggest
that growth during development is atypical: these individuals are more likely
to be shorter at birth but taller as adults, or taller at birth but shorter as
adults (Gunnell et al,
2003,
2005a). This suggests
that people who develop psychosis in adulthood may experience `catch-up' or
`catch-down' growth during development. Our study was unable to contrast the
growth patterns of individuals in the SSD group who were smaller at birth and
those who were larger because few participants fell into these categories. A
second way to identify whether catch-up growth occurred is to examine whether
individuals in the female SSD group grew more rapidly than those in the female
non-SSD group during later childhood; however, this is not evident from our
data. None the less, it is possible that catch-up growth might occur later in
development. Future assessments of adolescent growth are necessary to explore
this theory further.
Growth hormone–insulin-like growth factor axis
Our finding of slower growth velocity during early life in women with
schizophrenia adds to the accumulating evidence that mechanisms responsible
for the regulation of physical growth may have a role in the pathogenesis of
this disorder. Although the connection between growth and schizophrenia
remains to be fully elucidated, the extant literature suggests that slower
growth during infancy is indicative of premorbid disruption in the growth
hormone–insulin-like growth factor (GH–IGF) axis, which plays a
major part in the regulation of both prenatal and postnatal growth
(Le Roith et al,
2001). Growth during prenatal development and infancy is primarily
regulated by IGF–1, as well as by insulin and nutrition, whereas growth
hormone begins to play a critical part during late infancy and early childhood
(Karlberg et al,
1987).
Although no previously published study has examined the association between IGF–1 levels during infancy and postnatal growth in babies born of average size, a study of adults found that lower adult IGF–1 was associated with a deceleration in growth during the first year of life, but not with birth length, weight or ponderal index (Ben-Shlomo et al, 2003). The results from a longitudinal assessment of a large cohort suggest that IGF–1 may also be influential in regulating growth during childhood (Rogers et al, 2006).
The link between IGF–1 and other adult diseases such as heart disease, diabetes and hypertension has already been established (Barker et al, 1993; Sandhu et al, 2002). The association between birth weight and adult coronary heart disease prompted the theory that poor foetal nutrition or an insult during a critical period of development might have a long-term impact on an individual's risk of developing a number of chronic diseases later in life –referred to as the `foetal origins of disease hypothesis' (Barker, 1994). More recently it has been suggested that exposures operating throughout the life course might have a long-term impact on adult disease risk (Ben-Shlomo & Kuh, 2002). One biological mechanism that might mediate associations of foetal and childhood growth with adult disease is perturbation of the GH–IGF axis, leading to reduced IGF–1 secretion (Barker et al, 1993; Fall et al, 1995). It has been suggested that if disruption of the GH–IGF axis occurs, growth during infancy would most probably be the period of development affected (Fall et al, 1995) because IGF–1 is more influential during infancy than during any other developmental period. Although there are alternative explanations, research linking schizophrenia and prenatal exposures such as maternal infection (Brown, 2006) and poor prenatal nutrition (Susser & Lin, 1992) provides support for the foetal origins of disease hypothesis as a potential explanation for the association between slower postnatal growth and schizophrenia.
IGF-1, neurodevelopment and schizophrenia
Although the idea is speculative, it is worth considering that a disruption
in IGF–1 might be a cause of abnormalities in neuro-development
consistent with schizophrenia. This has been postulated to explain the
observation that adults with schizophrenia are typically shorter than healthy
controls, and such disruption may also be partially responsible for documented
neurological abnormalities such as ventricular enlargement
(Gunnell & Holly,
2004).
Our findings should also be considered in light of the literature on other premorbid disturbances in schizophrenia. This body of work suggests that delays in speech and neuromotor development (Jones et al, 1994) and poor intellectual functioning (David et al, 1997) are early-life precursors of adult schizophrenia. The link between premorbid neurocognitive functioning and the GH–IGF axis is supported by a recent study of healthy children, which found a positive correlation between IGF–1 levels and performance on the Wechsler Intelligence Scale for Children (Gunnell et al, 2005b). Hence, it is possible that cognitive abnormalities and poor intellectual functioning observed prior to the development of schizophrenia might occur in part because of a dysregulation in the GH–IGF axis.
Nutrition
Nutrition also has a significant role in the regulation of growth during
early life (Karlberg, 1987).
Short stature and stunted growth due to malnutrition have been associated with
lower scores on tests of cognitive functioning and poor educational
achievement (Stathis et al,
1999; Strauss,
2000; Berkman et al,
2002). In order to explore the potential role of nutrition, we
assessed changes in weight and BMI during development using similar analyses
to those conducted for height. No significant difference in weight or BMI
between the SSD and non-SSD groups was found during early infancy. Although we
did not detect any difference in weight change during later childhood, there
was a trend toward slower change in BMI among participants in the SSD group.
This is consistent with previous studies demonstrating associations between
thinness in childhood (Wahlbeck et
al, 2001), low BMI in adolescence
(Gunnell et al,
2005a) and adult schizophrenia. Because our effect size
was small, further assessments are necessary to determine whether
malnourishment is responsible for the association between growth during
infancy and adult schizophrenia.
Gender differences
Another noteworthy finding from our study is that gender appears to
moderate the relationship between growth and schizophrenia. Women with
schizophrenia-spectrum disorder grew more slowly during their early life,
whereas men with the disorder did not. Although the precise neurobiological
mechanisms responsible for this finding are unclear, it is known that there
are gender differences not only in growth during early life, but also in
secretion of and sensitivity to growth hormone and IGF–1 during
development (Ong et al,
2002; Geary et al,
2003). Furthermore, gender differences in symptoms, age at onset,
clinical course and treatment outcome in schizophrenia have been well
documented (Leung & Chue,
2000). Brain imaging studies have also identified abnormal
patterns of sexually dimorphic areas in schizophrenia with gender-specific
differences in these abnormalities
(Goldstein et al,
2002). Hence, it is worth speculating that if females are more
sensitive to IGF–1, they might be differentially affected by a
disruption in the GH–IGF axis that could give rise to schizophrenia
through neurodevelopmental mechanisms. Clearly, further research is necessary
to determine the causes of gender-specific differences in the association
between growth during early life and schizophrenia.
Limitations of the study
Although the results from this study are informative, a few limitations
must be noted. First, since height is difficult to measure (especially during
infancy), and a systematic procedure was not implemented to enhance the
accuracy of measurements, it is possible that some of our measurements might
have been compromised by error. Since it is unlikely that individuals in the
SSD sample were more prone to measurement error than those in the non-SSD
sample, this would result in non-differential misclassification error
associated with height. Because the analysis included multiple measurements of
each individual, it is unlikely that measurement error would produce spurious
results. Second, we had to rely on maternal height as a proxy measure for
target height because there were insufficient data on paternal height. It is
unlikely that our inability to control properly for genetic height potential
compromised the results, because the estimates from the adjusted and
unadjusted models were comparable. Third, on average there were fewer
measurements of height during later childhood (six measurements) than in early
life (nine measurements). Fewer measurements might have limited the ability to
detect a difference in patterns of growth. Linear growth models are
sufficiently sensitive, however, to estimate individual growth trajectories
based on two data points, so that a reduction in the number of measurements
does not necessarily diminish our ability to detect a significant effect.
Fourth, our analysis included a modest number in the SSD group
(n=70), which might have reduced our power to detect a significant
difference. Future studies of patterns of growth including a larger number of
individuals with the disorder are necessary to provide more confidence in our
findings.
Regardless of these methodological considerations, our study provides further support for the hypothesis that growth during early development is atypical in individuals with schizophrenia. These results indicate that growth during early life is slower in girls –but not boys –who go on to develop schizophrenia. In contrast, growth velocity during later childhood was not associated with subsequent disease status. This work also adds to the accumulating evidence for a neurodevelopmental origin of schizophrenia. Future studies assessing factors important in the regulation of growth during early life, such as growth hormone and IGF–1, will be necessary to determine the molecular and cellular mechanisms underlying the potential relationship between slowed growth and schizophrenia.
|
|
|---|
|
|
|---|
Related articles in BJP:
This article has been cited by other articles:
![]() |
P. Tyrer Sentinels on the road to disaster. The British Journal of Psychiatry, October 1, 2009; 195(4): 378 - 378. [Full Text] [PDF] |
||||
![]() |
J. Lahti, K. Raikkonen, U. Sovio, J. Miettunen, A.-L. Hartikainen, A. Pouta, A. Taanila, M. Joukamaa, M.-R. Jarvelin, and J. Veijola Early-life origins of schizotypal traits in adulthood The British Journal of Psychiatry, August 1, 2009; 195(2): 132 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Welham, M. Isohanni, P. Jones, and J. McGrath The Antecedents of Schizophrenia: A Review of Birth Cohort Studies Schizophr Bull, May 1, 2009; 35(3): 603 - 623. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||